Merck to Participate in the UBS Global Healthcare Conference
06 November 2024 - 12:45PM
Business Wire
Merck (NYSE: MRK), known as MSD outside of the United States and
Canada, announced today that Jannie Oosthuizen, president, Human
Health U.S., and Dr. Joerg Koglin, senior vice president and head
of general medicine, global clinical development, Merck Research
Laboratories, are scheduled to participate in a fireside chat at
the UBS Global Healthcare Conference on Wednesday, Nov. 13, 2024,
at 12:30 p.m. EST / 9:30 a.m. PST.
Investors, analysts, members of the media and the general public
are invited to listen to a live audio webcast of the presentation
at this weblink.
About Merck
At Merck, known as MSD outside of the United States and Canada,
we are unified around our purpose: We use the power of leading-edge
science to save and improve lives around the world. For more than
130 years, we have brought hope to humanity through the development
of important medicines and vaccines. We aspire to be the premier
research-intensive biopharmaceutical company in the world – and
today, we are at the forefront of research to deliver innovative
health solutions that advance the prevention and treatment of
diseases in people and animals. We foster a diverse and inclusive
global workforce and operate responsibly every day to enable a
safe, sustainable and healthy future for all people and
communities. For more information, visit www.merck.com and connect
with us on X (formerly Twitter), Facebook, Instagram, YouTube and
LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway,
N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA
(the “company”) includes “forward-looking statements” within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s Annual
Report on Form 10-K for the year ended December 31, 2023 and the
company’s other filings with the Securities and Exchange Commission
(SEC) available at the SEC’s Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241106053479/en/
Media Contacts: Robert Josephson (203) 914-2372
robert.josephson@merck.com Michael Levey (215) 872-1462
michael.levey@merck.com
Investor Contacts: Peter Dannenbaum (732) 594-1579
peter.dannenbaum@merck.com Steven Graziano (732) 594-1583
steven.graziano@merck.com
Merck (NYSE:MRK)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Dez 2023 bis Dez 2024